there have been successes in , in partd vaccines because of the collaborations and work mby bartha. but the majority of manufacturers are still continuing to produce a-based best scenes -- eggs based vaccines. there are reasons for this. they are safe and effective. changewould manufacturing. we believe it is worth understanding on alternatives. some say they could be more vocations than a debased vaccines, but no more analysis -- but more analysis is needed. we are using cms data to compare for the patients vaccines to determine which was more effective in that population. as we consider greater investments, it is important to note that there are challenges with these cell-based approaches. to help address these challenges, we are working on different cell lines. we are also looking on how to develop more robust manufacturing process to increase yields. continuous manufacturing holds great progress because supply could be more easily ramped up on short notice. this would allow us to rapidly address strange rift and getting all the necessary repertory work done is one limiting step